Mode
Text Size
Log in / Sign up
Phase 4 Completed N=346 Randomized Quadruple-blind Treatment

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Source: ClinicalTrials.gov NCT02959983 ↗
Enrolled (actual)
346
Serious AEs
1.2%
Results posted
Feb 2019
Primary outcomePrimary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores — 22.7; 10.3 percentage of participants — p=0.0022
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores
22.7; 10.3 0.0022 sig
SECONDARY
Percentage of Stool Consistency Responders
27.9; 16.7; 24.4; 12.6; 30.8; 20.1 0.0119 sig
SECONDARY
Percentage of Pain Responders
43.6; 31.0; 30.2; 25.9; 45.9; 31.6 0.0174 sig
SECONDARY
Percentage of Monthly Composite Responders
14; 6.9; 26.7; 14.9; 30.8; 16.7 0.0330 sig

Eligibility Criteria

Inclusion Criteria

  • Has a diagnosis of IBS-D, defined by the Rome III criteria as loose (mushy) or watery stools ≥25% and hard or lumpy stools ≤25% of bowel movements.
  • Has had a colonoscopy performed within 5 years prior to Screening if they are at least 50 years of age, OR if they meet any of the following alarm features:
  • Has documented weight loss within the past 6 months; or
  • Has nocturnal symptoms; or
  • Has a familial history of colon cancer; or
  • Has blood mixed with their stool (excluding any blood from hemorrhoids)
  • Patient reports use of loperamide in the 12 months prior to Screening for IBS-D symptoms and that loperamide did not provide adequate control of IBS-D symptoms.
  • Has not used any loperamide rescue medication within 14 days prior to randomization.

Exclusion Criteria

  • Has a diagnosis of Irritable Bowel Syndrome (IBS) with a subtype of constipation IBS, mixed IBS, or unsubtyped IBS.
  • Has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis), microscopic colitis, or celiac disease.
  • Has a history of diverticulitis within 3 months prior to screening.
  • Has a documented history of lactose intolerance.
  • Has a documented history of bile-acid malabsorption.
  • Has a history of chronic or severe constipation or intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions.
  • Has any of the following surgical history:
  • Cholecystectomy or previously documented agenesis of gallbladder; or
  • Any abdominal surgery within the 3 months prior to screening; or
  • Major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed).
  • Has a history of cholecystitis within 6 months before screening.
  • Has a history of pancreatitis or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction.
  • Has a history of known or suspected biliary duct obstruction or sphincter of Oddi disease or dysfunction, excluding a history of gallstones.
  • Has a history or current evidence of laxative abuse within 5 years prior to screening.
  • Has documented evidence of cirrhosis.
  • Has a history of cardiovascular events, including stroke, myocardial infarction, congestive heart failure, or transient ischemic attack within 6 months prior to screening.
  • Has an unstable renal, hepatic, metabolic, or hematologic condition.
  • Has a history of malignancy within 5 years before screening (except squamous and basal cell carcinomas and cervical carcinoma in situ).
  • Has a history of human immunodeficiency virus infection.
  • Has a history of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision-defined substance dependency, excluding nicotine and caffeine, within 2 years prior to screening.
  • Has a history of alcohol abuse, alcohol addiction, and alcoholism or drinks more than 3 alcoholic beverages per day.
  • Has used aspirin or aspirin-containing medications (>325 mg of aspirin per day) or nonsteroidal anti-inflammatory drugs, when taken specifically for the symptoms of IBS, within 14 days of randomization.
  • Has current (within 14 days of randomization) or expected use of any narcotic or opioid-containing agents, tramadol, docusate, enemas, GI preparations (including antacids containing aluminum or magnesium, antidiarrheal agents [except loperamide rescue medication after randomization]), antinausea agents, antispasmodic agents, bismuth, or prokinetic agents.
  • Has current (within 28 days of randomization) use of rifaximin or other antibiotics (with the exception of topical antibiotics or a 1-day course with an antibiotic). Expected use of rifaximin or other antibiotics during the course of the study that is known at the time of randomization.
  • Has an elective surgery planned or expects to need elective surgery at an
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02959983). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search